Navigation Links
Pharmaxis Appoints Portuguese Distributor for Aridol

SYDNEY, Australia, Dec. 14 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of Pulmocor SA to market and distribute its asthma diagnostic tool, Aridol in Portugal.

"Portugal was one of the 13 European countries included in the successful mutual recognition procedure earlier this year," said Pharmaxis Chief Executive Officer Dr Alan Robertson.

"Bronchial challenge testing is a common procedure in Potuguese hospitals and we have sought a distributor that already has a strong franchise in this market and will provide the best support for Aridol; we are delighted to announce our agreement with Pulmocor."

Mr Ricardo Villar, President of Pulmocor said, "Founded in 1982, Pulmocor has a strong reputation for quality and excellence among respiratory specialists and brings many years of bronchial challenge testing experience to the promotion of Aridol. Pulmocor is currently extending its activity into specialist pharmaceutical products and Aridol represents an important addition to our portfolio and our ability to service respiratory specialists."

Aridol has already been approved in Europe by the mutual recognition procedure and is now awaiting confirmation of national approval in Portugal.

A simple to use airways inflammation test, Aridol is administered as a dry powder in a hand held inhaler. Doctors can use the results of this test to identify airway hyper-responsiveness -- a hallmark of asthma.

To find out more about Pharmaxis go to .

To find out more about Aridol go to diseases-and-products/our-products/our-products_home.cfm .

(Note: If the URL above wraps to a second line, paste both lines into the browser.)

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.


Alan Robertson - Chief Executive Officer

Tel: +61-2-9454-7200


Released through:

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915



Felicity Moffatt

Tel: +61-418-677-701


SOURCE Pharmaxis Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Phase III Trial Finds Pharmaxis Bronchitol Effective
2. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
3. Pharmaxis Closes Share Purchase Plan
4. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
5. Codexis Appoints Singapore Laboratories Managing Director
6. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
10. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):